ClinicalTrials.gg
CompletedNCT07214922Updated Dec 23, 2025Results posted

Relative Bioavailability of Evobrutinib Tablet Batches

A Phase 1 interventional study of Treatment A and Treatment B in Healthy, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-23.

Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Jan 2023, registered Oct 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The main purpose of the study is to compare the Pharmacokinetics (PK), safety and tolerability of different manufacturing batches of M2951 tablet formulation relative to a reference batch under fasted conditions in healthy participants.

02

Conditions studied

  • Healthy

Keywords

  • Evobrutinib
  • Pharmacokinetics
  • Relative Bioavailability
  • Crossover
03

In context

Lead sponsor

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who are overtly healthy as determined by medical evaluation, including no abnormality identified on physical examination or laboratory evaluation and no active clinically significant disorder, condition, infection, or disease that would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion
  • Participants who have a body weight within 50.0 and 100.0 kilogram (kg) (inclusive) and within the range 19.0 and 30.0 kg/ meter square (m2) (inclusive)
  • Female participant who agrees to use appropriate and barrier methods.
  • Male participants: No contraception needed
  • Participants who are capable of giving signed which includes compliance with the requirements and restrictions listed in the ICF and this protocol
  • Participants who are stable non-smokers for at least 3 months preceding Screening
  • Other protocol defined inclusion criteria could apply

Exclusion criteria

Exclusion Criteria:

  • Participants with history or presence of respiratory, gastrointestinal, renal, hepatic, hematological, lymphatic, neurological, cardiovascular, musculoskeletal, genitourinary, immunological, dermatological, connective tissue, psychiatric (due to rare risk of hallucinations, agitation and activation of psychosis), and other diseases or disorders, and epilepsy, as determined by medical evaluation
  • Participants with diagnosis of hemochromatosis, Wilson´s disease, alpha 1 antitrypsin deficiency, or any other chronic liver disease including Gilbert's disease will be excluded from the study
  • Participants with prior history of cholecystectomy or splenectomy, and any clinically relevant surgery within 6 months prior to the first administration of study intervention
  • Participants with history of any
  • Participants with history of seizures
  • Participants with history of pharmacologically treated psychiatric disease
  • Participants with history of chronic or recurrent acute infection or any bacterial, viral, parasitic or fungal infections within 30 days prior to Screening and at any time between Screening and admission, or hospitalization due to infection within 6 months prior to the first administration of study intervention
  • Participants with history of shingles within 12 months prior to Screening
  • Participants with history of drug
  • Participants with history of residential exposure to tuberculosis, or a positive QuantiFERON® test within 4 weeks prior to or at the time of Screening
  • Participants positive for

    1. surface antigen, hepatitis B core antibody, antibody, or (HIV) I and II tests at Screening
    2. severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at Screening and Day -1
  • Participants with any condition, including findings in the laboratory tests, medical history (example heart failure, hypokalemia, family history of Long Syndrome), or other Screening assessments, that in the opinion of the Investigator constitutes an inappropriate risk or a for participation in the study or that could interfere with the study's objectives, conduct, or evaluation
  • Participants with history of administration of or live-attenuated virus vaccines within 3 months prior to Day 1.
  • Participants with history of administration of other types of vaccines is allowed until 14 days before the first administration of study intervention, thereafter it is prohibited until the end of the study.
  • Participants with Moderate or strong inhibitors or inducers of Cytochrome P450 3A4 ()/5 or Pgp within 4 weeks prior to the first administration of study intervention
  • Participants with use of any prescribed medicine or over-the-counter drug or dietary supplement, including herbal remedies, vitamins, and minerals, antacids and dietary supplements such as fish oils within 2 weeks or 5 times the half-life of the respective drug, whichever is longer, prior to the first administration of study intervention
  • Participants with use of any drug in any clinical study within 60 days prior to Day 1 administration, or have used an experimental monoclonal antibody within the past 1 year prior to Day 1, or have participated in a study evaluating a Bruton Tyrosine Kinase (BTK) inhibitor within 60 days, or are on extended follow-up in a clinical study, even if last administration of a study intervention was more than 60 days ago, or 5 half-lives of the investigational drug, whichever is longer, prior to the first administration of study intervention
  • Participants with a medical history and physical examination results that include any ongoing clinically relevant findings as judged by the Investigator
  • Participants with clinically relevant findings (excluding minor, not clinically relevant excursions from normal ranges, as judged by the Investigator) at Screening in biochemistry, hematology, coagulation, and urinalysis examinations for the age of the participant, as judged by the Investigator:

    • , aspartate aminotransferase: above (ULN)
    • Creatinine: above normal limits
    • Absolute lymphocyte count, : below limit of reference range.
    • Amylase and lipase above normal ranges; minor deviations are allowed, if not clinically relevant.
  • Participants with estimated glomerular rate () according to the Chronic Kidney Disease Epidemiology Collaboration Creatinine Equation (2009) \< 90 milliliters/minute(mL/min) at Screening. In case of a borderline result between ≥ 80 and \< 90 mL/min, Cystatin C will be determined in addition, and the participant will only be included if the Cystatin C value is below the upper limit of normal
  • Participants with semi-supine systolic blood pressure > 140 mmHg or \< 90 millimeters of mercury (mmHg), diastolic blood pressure > 90 mmHg or \< 50 mmHg, and pulse rate > 90 or \< 50 beats per minute (bpm) at Screening.
  • Participants with consumption of alcohol from 48 hours prior to first administration of study intervention.
  • Other protocol defined exclusion criteria could apply
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Evobrutinib: Treatment Sequence 1: ABCD

    Participants will receive single oral dose of Treatment A on Day 1 in period 1, followed by single oral dose of Treatment B on Day 3 in period 2, followed by Treatment C on Day 5 in period 3 and followed by single oral dose of Treatment D on Day 7 under fasted condition in period 4. There will be 48 hours washout period between each treatment period.

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D

  • Experimental
    Evobrutinib: Treatment Sequence 2: BDAC

    Participants will receive single oral dose of Treatment B on Day 1 in period 1, followed by single oral dose of Treatment D on Day 3 in period 2, followed by Treatment A on Day 5 in period 3 and followed by single oral dose of Treatment C on Day 7 under fasted condition in period 4. There will be 48 hours washout period between each treatment period.

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D

  • Experimental
    Evobrutinib: Treatment Sequence 3: CADB

    Participants will receive single oral dose of Treatment C on Day 1 in period 1, followed by single oral dose of Treatment A on Day 3 in period 2, followed by Treatment D on Day 5 in period 3 and followed by single oral dose of Treatment B on Day 7 under fasted condition in period 4. There will be 48 hours washout period between each treatment period.

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D

  • Experimental
    Evobrutinib: Treatment Sequence 4: DCBA

    Participants will receive single oral dose of Treatment D on Day 1 in period 1, followed by single oral dose of Treatment C on Day 3 in period 2, followed by Treatment B on Day 5 in period 3 and followed by single oral dose of Treatment A on Day 7 under fasted condition in period 4. There will be 48 hours washout period between each treatment period.

    Drug: Treatment A · Drug: Treatment B · Drug: Treatment C · Drug: Treatment D

Interventions

  • Participants will receive single dose of Treatment A in treatment period 1, 2, 3 or 4 under fasted conditions.

    Also known as: Evobrutinib

  • Participants will receive single dose of Treatment B in treatment period 1, 2, 3 or 4 under fasted conditions.

    Also known as: Evobrutinib

  • Participants will receive single dose of Treatment C in treatment period 1, 2, 3 or 4 under fasted conditions.

    Also known as: Evobrutinib

  • Participants will receive single dose of Treatment D in treatment period 1, 2, 3 or 4 under fasted conditions.

    Also known as: Evobrutinib

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib

    AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7

  2. Maximum Observed Plasma Concentration (Cmax) of Evobrutinib

    Cmax was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7

Secondary outcomes

  1. Number of Participants With Treatment- Emergent Adverse Events (TEAEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs.

    Time frame: Up to 34 days

  2. Number of Participants With Treatment- Emergent Adverse Events (TEAEs) by Severity

    The Investigator assessed the severity of each AE and SAE reported during the study and assign it to one of the following categories: Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities; Severe: An event that prevents normal everyday activities. Do not confuse an AE that is assessed as severe with a SAE. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe.

    Time frame: Up to 34 days

  3. Change From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure

    Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

    Time frame: Baseline (Pre-dose), 2 hours post-dose

  4. Change From Baseline in Vital Signs: Temperature

    Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

    Time frame: Baseline (Pre-dose), 2 hours post-dose

  5. Change From Baseline in Vital Signs: Pulse Rate

    Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

    Time frame: Baseline (Pre-dose), 2 hours post-dose

  6. Change From Baseline in Vital Signs: Respiratory Rate

    Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

    Time frame: Baseline (Pre-dose), 2 hours post-dose

  7. Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate

    Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions

    Time frame: Baseline (Pre-dose), 2 hours post-dose

  8. Change From Baseline in Electrocardiograms (ECGs) Parameter: RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration

    RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

    Time frame: Baseline (Pre-dose), 2 hours post-dose

  9. Number of Participants With Clinically Significant Changes in Laboratory Parameters

    Laboratory investigation included hematology, biochemistry and urinalysis. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. Clinical significance was determined by the investigator.

    Time frame: Screening up to Day 8

  10. Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Evobrutinib

    The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification (LLOQ). Calculated using the mixed log-linear trapezoidal rule (linear up, log down).

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7

  11. Time to Reach Maximum Observed Plasma Concentration (Tmax) of Evobrutinib

    Time to reach the maximum observed plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7

  12. Terminal Half Life (T1/2) of Evobrutinib

    Terminal half-life was calculated as log2 divided by lambda z. Lambda z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7

  13. Apparent Total Body Clearance (CL/f) of Evobrutinib

    Apparent total body clearance of drug from plasma following extravascular administration, calculated as dose/AUC0-infinity for Evobrutinib.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7

  14. Apparent Volume of Distribution During Terminal Phase (VZ/f) of Evobrutinib

    Vz/f is defined as the apparent volume of distribution during the terminal phase following extravascular administration for Evobrutinib.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7

  15. Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Evobrutinib (Treatment B, C and D) Compared to Evobrutinib Reference Treatment A

    Relative Bioavailability in percentage of each treatment (B, C, and D) in relation to the reference Treatment (A) was calculated as Frel = 100 multiplied by (AUC0-inf \[treatment B, C, D\]) multiplied by Dose \[treatment A\] divided by (AUC0-inf \[treatment A\]) multiplied by Dose \[treatment B, C, D\]. Treatment A to determine relative bioavailability.

    Time frame: Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7

07

Results

Posted Dec 23, 2025

Participant flow

Participant flow — Overall Study
MilestoneSequence 1: Treatment A-B-C-DSequence 2: Treatment B-D-A-CSequence 3: Treatment C-A-D-BSequence 4: Treatment D-C-B-A
Started7777
Completed7667
Not completed0110
Withdrew: Adverse event0010
Withdrew: Dropped out on day 5; private reasons0100

Outcome measures

PrimaryArea Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib

AUC0-inf was calculated by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Clast pred/Lambda z, where Clast pred was the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLOQ) and Lambda z was the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Reported as:
Geometric mean · hour×nanogram per milliliter (h×ng/mL)
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib
hour×nanogram per milliliter (h×ng/mL)Treatment ATreatment BTreatment CTreatment D
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Evobrutinib198 ± 44.0164 ± 45.1207 ± 44.6205 ± 38.3
PrimaryMaximum Observed Plasma Concentration (Cmax) of Evobrutinib

Cmax was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Reported as:
Geometric mean · nanogram per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib
nanogram per milliliter (ng/mL)Treatment ATreatment BTreatment CTreatment D
Maximum Observed Plasma Concentration (Cmax) of Evobrutinib111 ± 69.984.5 ± 71.9117 ± 62.6121 ± 64.7
SecondaryNumber of Participants With Treatment- Emergent Adverse Events (TEAEs)

An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether considered related to the study intervention or not. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs were defined as events with onset date or worsening during the on-treatment period. TEAEs included both serious and non-serious TEAEs.

Time frame:
Up to 34 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)
ParticipantsTreatment ATreatment BTreatment CTreatment D
Number of Participants With Treatment- Emergent Adverse Events (TEAEs)2125
SecondaryNumber of Participants With Treatment- Emergent Adverse Events (TEAEs) by Severity

The Investigator assessed the severity of each AE and SAE reported during the study and assign it to one of the following categories: Mild: An event that is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities; Moderate: An event that causes sufficient discomfort and interferes with normal everyday activities; Severe: An event that prevents normal everyday activities. Do not confuse an AE that is assessed as severe with a SAE. Severe is a category used to rate the intensity of an event; both AEs and SAEs can be assessed as severe.

Time frame:
Up to 34 days
Reported as:
Count of participants · Participants
Number of Participants With Treatment- Emergent Adverse Events (TEAEs) by Severity
ParticipantsTreatment ATreatment BTreatment CTreatment D
Mild2004
Moderate0111
Severe0010
SecondaryChange From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure

Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

Time frame:
Baseline (Pre-dose), 2 hours post-dose
Reported as:
Mean · millimeters of mercury (mmHg)
Change From Baseline in Vital Signs: Systolic Blood Pressure and Diastolic Blood Pressure
millimeters of mercury (mmHg)Treatment ATreatment BTreatment CTreatment D
Systolic Blood Pressure0 ± 10.4-1 ± 7.3-1 ± 6.9-1 ± 7.0
Diastolic Blood Pressure-1 ± 5.8-1 ± 5.80 ± 6.0-1 ± 4.7
SecondaryChange From Baseline in Vital Signs: Temperature

Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

Time frame:
Baseline (Pre-dose), 2 hours post-dose
Reported as:
Mean · degree Celsius
Change From Baseline in Vital Signs: Temperature
degree CelsiusTreatment ATreatment BTreatment CTreatment D
Change From Baseline in Vital Signs: Temperature0.2 ± 0.270.2 ± 0.340.0 ± 0.240.0 ± 0.27
SecondaryChange From Baseline in Vital Signs: Pulse Rate

Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

Time frame:
Baseline (Pre-dose), 2 hours post-dose
Reported as:
Mean · beats per minute
Change From Baseline in Vital Signs: Pulse Rate
beats per minuteTreatment ATreatment BTreatment CTreatment D
Change From Baseline in Vital Signs: Pulse Rate-2 ± 8.5-1 ± 8.6-3 ± 8.3-2 ± 7.3
SecondaryChange From Baseline in Vital Signs: Respiratory Rate

Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

Time frame:
Baseline (Pre-dose), 2 hours post-dose
Reported as:
Mean · breaths per minute
Change From Baseline in Vital Signs: Respiratory Rate
breaths per minuteTreatment ATreatment BTreatment CTreatment D
Change From Baseline in Vital Signs: Respiratory Rate0 ± 2.5-1 ± 2.0-1 ± 1.9-0 ± 2.0
SecondaryChange From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate

Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions

Time frame:
Baseline (Pre-dose), 2 hours post-dose
Reported as:
Mean · beats per minute
Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate
beats per minuteTreatment ATreatment BTreatment CTreatment D
Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate-4 ± 6.1-2 ± 4.0-2 ± 6.6-1 ± 4.7
SecondaryChange From Baseline in Electrocardiograms (ECGs) Parameter: RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration

RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions.

Time frame:
Baseline (Pre-dose), 2 hours post-dose
Reported as:
Mean · millisecond (msec)
Change From Baseline in Electrocardiograms (ECGs) Parameter: RR Duration, QT Duration, QTcF Duration, PR Duration, QRS Duration
millisecond (msec)Treatment ATreatment BTreatment CTreatment D
RR Duration52 ± 84.636 ± 61.344 ± 106.418 ± 70.3
QT Duration9 ± 10.96 ± 9.810 ± 10.74 ± 10.1
QTcF Duration1 ± 11.81 ± 9.54 ± 8.92 ± 8.7
PR Duration-5 ± 7.8-1 ± 6.1-0 ± 8.00 ± 5.8
QRS Duration-0 ± 4.9-1 ± 4.91 ± 4.8-1 ± 4.6
SecondaryNumber of Participants With Clinically Significant Changes in Laboratory Parameters

Laboratory investigation included hematology, biochemistry and urinalysis. The number of participants with clinically significant changes from baseline in laboratory parameters were reported. Clinical significance was determined by the investigator.

Time frame:
Screening up to Day 8
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Laboratory Parameters
ParticipantsTreatment ATreatment BTreatment CTreatment D
Number of Participants With Clinically Significant Changes in Laboratory Parameters0000
SecondaryArea Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Evobrutinib

The AUC from time zero (= dosing time) to the last sampling time (tlast) at which the concentration is at or above the lower limit of quantification (LLOQ). Calculated using the mixed log-linear trapezoidal rule (linear up, log down).

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Reported as:
Geometric mean · h×ng/mL
Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Evobrutinib
h×ng/mLTreatment ATreatment BTreatment CTreatment D
Area Under the Plasma Concentration Time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUC0-t) of Evobrutinib194 ± 44.5160 ± 46.3204 ± 45.1202 ± 39.2
SecondaryTime to Reach Maximum Observed Plasma Concentration (Tmax) of Evobrutinib

Time to reach the maximum observed plasma concentration (Tmax) was obtained directly from the concentration versus time curve.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Reported as:
Median · hours
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Evobrutinib
hoursTreatment ATreatment BTreatment CTreatment D
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Evobrutinib1.00 (0.500 to 1.50)1.00 (0.500 to 2.00)1.00 (0.250 to 1.50)1.00 (0.500 to 2.00)
SecondaryTerminal Half Life (T1/2) of Evobrutinib

Terminal half-life was calculated as log2 divided by lambda z. Lambda z was terminal elimination rate constant determined from the terminal slope of the log-transformed plasma concentration curve.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Reported as:
Median · hours
Terminal Half Life (T1/2) of Evobrutinib
hoursTreatment ATreatment BTreatment CTreatment D
Terminal Half Life (T1/2) of Evobrutinib1.64 (1.01 to 10.8)1.78 (1.05 to 13.7)1.72 (1.07 to 15.6)1.37 (0.982 to 5.41)
SecondaryApparent Total Body Clearance (CL/f) of Evobrutinib

Apparent total body clearance of drug from plasma following extravascular administration, calculated as dose/AUC0-infinity for Evobrutinib.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Reported as:
Geometric mean · Liter per hour
Apparent Total Body Clearance (CL/f) of Evobrutinib
Liter per hourTreatment ATreatment BTreatment CTreatment D
Apparent Total Body Clearance (CL/f) of Evobrutinib227 ± 44.0275 ± 45.1217 ± 44.6219 ± 38.3
SecondaryApparent Volume of Distribution During Terminal Phase (VZ/f) of Evobrutinib

Vz/f is defined as the apparent volume of distribution during the terminal phase following extravascular administration for Evobrutinib.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Reported as:
Geometric mean · Liters
Apparent Volume of Distribution During Terminal Phase (VZ/f) of Evobrutinib
LitersTreatment ATreatment BTreatment CTreatment D
Apparent Volume of Distribution During Terminal Phase (VZ/f) of Evobrutinib627 ± 84.1843 ± 111.4658 ± 89.2522 ± 74.2
SecondaryRelative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Evobrutinib (Treatment B, C and D) Compared to Evobrutinib Reference Treatment A

Relative Bioavailability in percentage of each treatment (B, C, and D) in relation to the reference Treatment (A) was calculated as Frel = 100 multiplied by (AUC0-inf \[treatment B, C, D\]) multiplied by Dose \[treatment A\] divided by (AUC0-inf \[treatment A\]) multiplied by Dose \[treatment B, C, D\]. Treatment A to determine relative bioavailability.

Time frame:
Pre-dose, 0.25, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 hours post-dose on Days 1, 3, 5 and 7
Reported as:
Geometric mean · percentage bioavailability
Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Evobrutinib (Treatment B, C and D) Compared to Evobrutinib Reference Treatment A
percentage bioavailabilityTreatment BTreatment CTreatment D
Relative Bioavailability Based on Area Under the Plasma Concentration Curve From Time Zero Extrapolated to Infinity [Frel(AUC0-inf)] of Evobrutinib (Treatment B, C and D) Compared to Evobrutinib Reference Treatment A84.0 (75.8 to 93.1)105 (98.1 to 112)106 (98.0 to 115)

Adverse events

Collected over Up to 34 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment A0/26 (0%)0/26 (0%)2/26 (7.7%)
Treatment B0/27 (0%)0/27 (0%)1/27 (3.7%)
Treatment C0/27 (0%)1/27 (3.7%)1/27 (3.7%)
Treatment D0/27 (0%)0/27 (0%)5/27 (18.5%)
Most frequent serious events
Most frequent serious events
EventTreatment ATreatment BTreatment CTreatment D
SeizureNervous system disorders0/260/271/270/27
Most frequent other events
Most frequent other events
EventTreatment ATreatment BTreatment CTreatment D
HeadacheNervous system disorders0/260/271/272/27
NasopharyngitisInfections and infestations1/260/270/271/27
DizzinessNervous system disorders1/260/270/271/27
HypersensitivityImmune system disorders0/260/270/271/27
Lipase increasedInvestigations0/261/270/270/27

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Sequence 1: Treatment A-B-C-DSequence 2: Treatment B-D-A-CSequence 3: Treatment C-A-D-BSequence 4: Treatment D-C-B-ATotal
Mean30 ± 5.637 ± 10.137 ± 12.835 ± 10.435 ± 9.9
Sex: Female, Male
Sex: Female, Male(Participants)Sequence 1: Treatment A-B-C-DSequence 2: Treatment B-D-A-CSequence 3: Treatment C-A-D-BSequence 4: Treatment D-C-B-ATotal
Female453517
Male324211
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Sequence 1: Treatment A-B-C-DSequence 2: Treatment B-D-A-CSequence 3: Treatment C-A-D-BSequence 4: Treatment D-C-B-ATotal
Hispanic or Latino01001
Not Hispanic or Latino767727
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Sequence 1: Treatment A-B-C-DSequence 2: Treatment B-D-A-CSequence 3: Treatment C-A-D-BSequence 4: Treatment D-C-B-ATotal
American Indian or Alaska Native00000
Asian00000
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White777728
More than one race00000
Unknown or Not Reported00000
08

Study locations

1 site
  • Nuvisan GmbH
    Neu-Ulm, 89231, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and the European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2023 to primary completion in Feb 2023, 1 month.

Results were first posted in Dec 2025, 2 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 8, 2025
First posted
Oct 9, 2025
StartActual
Jan 18, 2023
Primary completionActual
Feb 24, 2023
CompletionActual
Feb 24, 2023
Results first posted
Dec 23, 2025
Last update
Dec 23, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 23, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07214922
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
Jan 18, 2023
Primary completion
Feb 24, 2023
Completion
Feb 24, 2023
Results posted
Dec 23, 2025
Last update
Dec 23, 2025

Study contacts

Medical Responsible
study director · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion